RxSight appoints new CEO
Seeking Alpha ·
RxSight ( RXST ) appointed Aziz Mottiwala as president and chief executive officer, effective July 20, 2026. Mottiwala succeeds Ron Kurtz, M.D., who will remain with the company as chief medical officer. Mottiwala most recently served as chief commercial officer at Tarsus Pharmaceuticals. RxSight: After Dropping To The Bottom, It's Time To Pick It Up RxSight: Alcon Deal Reshapes The Long-Term Growth Story RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript RxSight anticipates $140M to $160M 2026 revenue as Alcon collaboration adds $30M to $40M Alcon collaborates with RxSight to develop adjustable PCIOLs
AI 시장 분석
RxSight has appointed Aziz Mottiwala as its new CEO. Mottiwala will take his position from July 20, 2026, and currently serves as the Chief Commercial Officer at Tarsus Pharmaceuticals. RxSight expects revenues of $140M to $160M in 2026, with an additional $30M to $40M from collaborations with Alcon.
상승 영향
- Medical Equipment — Collaboration with Alcon is expected to increase revenue, while the new CEO's appointment is expected to restructure the company's growth strategy.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 33% · Bearish (Short) 67%
375 participants